Immediate versus delayed repair of partial mastectomy defects in breast conservation

Sj Kronowitz,E Strom,H Kuerer,Kk Hunt,Gl Robb,Ta Buchholz,Je Ensor,Ca Koutz

doi:10.1186/bcr2269

Sj Kronowitz, E Strom + Show 6 more

Open Access

https://doi.org/10.1186/bcr2269

Copy DOI

Abstract

The authors previously compared the local tissue rearrangement, breast reduction, and latissimus dorsi flap reconstruction techniques for repairing partial mastectomy defects and showed the benefits of breast reduction.

Highlights

The authors previously compared the local tissue re- In order to maintain a blood supply to the nipple areolar complex, some arrangement, breast reduction, and latissimus dorsi flap reconstruction breast tissue must be left behind
The authors provide practical guidelines for repairing a partial mastectomy defect using breast reduction that should minimize the occurrence of complications and optimize the cosmetic outcome [1]
The combination of on-treatment Ki67 with standard clinical features has allowed the derivation of a Preoperative Endocrine Therapy Index, which identified a group of patients with a very low likelihood of relapse on endocrine treatment alone [2]

Summary

Introduction

The authors previously compared the local tissue re- In order to maintain a blood supply to the nipple areolar complex, some arrangement, breast reduction, and latissimus dorsi flap reconstruction breast tissue must be left behind. The administration of BVZ plus first-line chemotherapy (paclitaxel, docetaxel) in the treatment of advanced breast carcinoma has lead to better outcomes in terms of response rate and time to progression in previous published studies. Results A total of 119 patients in 20 Spanish centers were included in the trial, with the following basal characteristics: median age 51 years (27 to 79); postmenopausal status, 83 patients (69.7%); estrogen receptor-positive, 64 patients (66.7%); HER2-negative, HER2-positive, unknown, 92 patients (95.8%), two patients (2.1%), two patients (2.1%), respectively; prior adjuvant therapy, 92 patients (95.8%) – anthracycline-based, 63 patients (72.4%) and taxane-based, 38 patients (43.6%). The present study compared the effect of two sequences of AI use – steroidal (exemestane (E)) and nonsteroidal (anastrozole (A)) – on serological and pathological biomarkers, when given in the neoadjuvant setting to patients with locally advanced breast cancer

Methods

Results

Conclusion